Celgene Corporation

October 9, 2017

First Myeloma Patient in Study Treated with New CAR T-Cell Therapy bb21217

The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate bb21217, developed under a joint ... Read more

March 17, 2017

Myeloma UK Launches Reolysin Combo Trial for Relapsing Myeloma Patients

News

The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma patients. The MUK eleven Phase ... Read more

June 16, 2016June 16, 2016

Study Reveals Multiple Myeloma Treatment Disparities Between Caucasian, African-American Patients

News

Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple myeloma, revealing there are discrepancies in treatment ... Read more